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Summary
 
Primary human immunodeficiency virus (HIV) infection is controlled principally by HIV-spe-
cific cytotoxic T lymphocytes (CTL) to a steady-state level of virus load, which strongly influ-
ences the ultimate rate of progression to disease. Epitope selection by CTL may be an impor-
tant determinant of the degree of immune control over the virus. This report describes the CTL
responses of two HLA-identical hemophiliac brothers who were exposed to identical batches
of Factor VIII and became seropositive within 10 wk of one another. Both have HLA-A
 
*
 
0201.
The CTL responses of the two siblings were very dissimilar, one donor making strong responses to
two epitopes within p17 Gag (HLA-A
 
*
 
0201–restricted SLYNTVATL and HLA-A3–restricted
RLRPGGKKK). The sibling responded to neither epitope, but made strong responses to two
epitopes presented by HLA-B7. This was not the result of differences in presentation of the
epitopes. However, mutations in both immunodominant epitopes of the p17 Gag responder
were seen in proviral sequences of the nonresponder. We then documented the CTL responses
to two HLA-A
 
*
 
0201–restricted epitopes, in Gag (SLYNTVATL) and Pol (ILKEPVHGV) in
22 other HIV-infected donors with HLA-A
 
*
 
0201. The majority (71%) generated responses to
the Gag epitope. In the 29% of donors failing to respond to the Gag epitope in standard assays,
there was evidence of low frequency memory CTL responses using peptide stimulation of
PBMC, and most of these donors also showed mutations in or around the Gag epitope. We
concluded that HLA class I genotype determines epitope selection initially but that mutation in
immunodominant epitopes can profoundly alter the pattern of CTL response.
C
 
TLs play a central role in the immune response to vi-
rus infections (1–4). In HIV infection, CTLs are re-
sponsible for the clearance of viremia after primary infec-
tion (5–6), and there is strong evidence that they also
contribute to prolongation of the disease-free phase of in-
fection (7–10). However, it is not possible to distinguish
slow progressors from rapid progressors on the basis of CTL
precursor frequency during this asymptomatic phase of in-
fection (9). One explanation is that CTL responses may dif-
fer qualitatively. Responses directed at more conserved re-
gions of the virus may be qualitatively superior, because there
is less scope for CTL escape mutation to occur without si-
multaneously damaging the fitness of the virus itself.
Support for qualitative differences in CTL responses de-
rives from studies of HLA associations with rate of progres-
sion in HIV infection. HLA class I molecules such as HLA-
B27, HLA-B57, and HLA-B51 have been linked with slow
progression, while HLA-B8 and HLA-B35 have been asso-
ciated with rapid development of disease in several studies
(11–13). In one study of slow progressors with HLA-B57,
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all seven donors tested made the immunodominant re-
sponse through HLA-B57 rather than any other of their
class I molecules (14).
The strong influence of the HLA class I genotype of an in-
dividual upon the selection of HIV-specific immunodominant
epitopes has been observed for HLA-B27 (10), HLA-B14
(15), and many other examples in other virus infections, for
example HLA-A11–restricted Epstein–Barr virus–specific re-
sponses (16). In general, patients with a given HLA type re-
act to HIV epitopes in a predictable way (17). Particular
MHC molecules may be associated with slow progression
because, by chance, the immunodominant epitopes selected
are relatively invariant. Switching an individual’s immuno-
dominant response away from a variable region of the virus
towards a highly conserved region might prove to be a
valuable therapeutic option.
It is not known what determines the immunodominance
of an individual’s CTL response. Possible selective events
include specificity of the proteases (18–19), TAP (antigen
processing-associated transporter)-dependent transport into
the endoplasmic reticulum (20–21), binding affinities of
peptides to class I molecules (22), and the stability of pep-
tide–MHC complexes on the cell surface (16, 23). Also, the
T cell repertoires may contribute significantly. Some CTL
responses to dominant epitopes are oligoclonal, with very
similar or even identical TCRs used in different individu-
als, implying selection among the T cells used by particular
epitopes (24–26).
We have studied two HLA-identical hemophiliac sib-
lings within a cohort of HIV-infected donors who have
HLA-A
 
*
 
0201. These brothers first tested seropositive within
10 wk of one another in 1983 and 1984, as a result of ex-
posure to an identical batch of HIV-contaminated Factor
VIII concentrate. The CTL responses of these HLA-identi-
cal siblings are substantially different, correlating with the
presence of striking epitope mutations within the provirus
of the nonresponder.
The CTL response of these and 22 other HLA-A
 
*
 
0201–
positive individuals to two well-defined HLA-A
 
*
 
0201–
restricted epitopes, SLYNTVATL (p17 Gag, HIV-1 LAI resi-
dues 77–85 [27]) and ILKEPVHGV (Pol, residues 476–484
[28]) has been plotted. The majority of donors generate
dominant responses to the Gag epitope, a minority prefer
the Pol epitope, and most of this latter group show muta-
tions in or around the Gag epitope.
 
Materials and Methods
 
Donors.
 
The 24 HLA-A
 
*
 
0201–positive adult donors were se-
lected from asymptomatic HIV-infected individuals attending
genito–urinary clinics in the Oxford Region, St. Mary’s Hospital
(London), or the Oxford Haemophilia Centre. No donors had
received antiretroviral therapy.
Donors 003 and 023 are HLA-identical hemophiliac brothers,
aged 27 and 25, respectively. Both 003 and 023, and also donor
008, were infected between August and December, 1983, after
infusion of a particular batch of HIV-contaminated Factor VIII
concentrate. These donors were exposed only to this single batch
of Factor VIII between August and December, 1983, inclusive,
during which donor 003 received 25,000 U and donor 023 re-
ceived 27,000 U (the mean usage for a hemophiliac being
 
z
 
30,000 U per yr; (Spooner, R., personal communication). Donor
023 first became seropositive for HIV in December, 1983 (aged
10 yr), while both 008 and 003 (aged 12 yr) first became seropos-
itive in February, 1984, having been seronegative previously. The
brothers 003 and 023, each having a natural factor VIII level of
 
,
 
1%, received very similar doses of Factor VIII. They have lived
in the same house throughout their lives; Factor VIII has been
exclusively home administered since 1976; all supplies of Factor
VIII have been shared; and there has been no batch of Factor VIII
of which one brother has received significantly more than the
other. The original batches of contaminated Factor VIII unfortu-
nately were unavailable for this study.
Donor 46M first presented in 1994 when her child was diag-
nosed as HIV infected. The route and duration of infection in
46M are unknown.
 
HLA Tissue Typing.
 
HLA tissue typing was performed by am-
plification refractory mutation system (ARMS)-PCR using se-
quence-specific primers (29).
 
Peptides.
 
Peptides were synthesised by Research Genetics,
Inc. (Huntsville, AL). The purity of the peptides was determined
by HPLC and the identity of the peptide confirmed by mass spec-
trometry measurement. Peptides were dissolved in DMSO and di-
luted in RPMI-1640 (Sigma Chem. Co., St. Louis, MO). Over-
lapping 15–20-mer peptides were supplied by the Medical Research
Council AIDS Directed Programme (MRC-ADP, Hertz, UK).
 
Recombinant Vaccinia Viruses.
 
Vaccinia virus recombinants ex-
pressing the HIV-1
 
pol
 
 and 
 
gp120
 
 genes were provided by the
MRC-ADP, the vaccinia expressing the 
 
gag
 
 gene was as described
previously (30), that expressing the 
 
nef
 
 gene was provided by Trans-
gene (Strasbourg, France), and the control influenza PB2 vaccinia
was kindly provided by Dr. B. Moss (National Institutes of
Health, Bethesda, MD).
 
Generation of Bulk Cultured CTL and Peptide-specific Lines.
 
Bulk-cultured CTLs were generated as previously described (30).
In brief, one-fifth of PBMC separated from whole blood were
added to the other four-fifths after 24 h stimulation with PHA to
activate expression of autologous HIV. These cells were cultured in
RPMI-1640 supplemented with antibiotics and 10% heat-inacti-
vated FCS (Globepharm, Esher, UK) (R10) for 7 d, after which
10% Lymphocult T (Biotest) was also added to the medium. Pep-
tide-specific lines were generated by pulsing PBMC with 100
 
m
 
M peptide for 1 h, followed by 3-d culture in R10 with added
IL-7 (40 ng/ml). Subsequent media exchanges were performed
using R10 containing 10% Lymphocult T. Assays were per-
formed on days 14–24 of culture.
 
Identification of Dominant CTL Responses.
 
Dominant responses
were established by assaying bulk CTL against autologous EBV-
transformed B-lymphoblastoid cells lines (BCL)
 
1
 
 infected with a
panel of vaccinia recombinants expressing HIV-1 
 
gp120
 
, 
 
gag
 
, 
 
pol
 
, and
 
nef
 
 genes. Overlapping peptides (MRC-ADP), 15–20 amino acids
in length, were then used to define the region(s) containing rec-
ognized epitopes. Additionally, previously defined epitopes pre-
sented by matching HLA class I molecules were tested for recog-
nition by bulk CTL.
 
CTL Assays.
 
Vaccinia-infected targets were infected with 3
PFU/cell for 90 min, washed, and incubated in R10 overnight.
In peptide-based assays, targets were pulsed with peptide for 1 h,
 
1
 
Abbreviations used in this paper:
 
 ARMS, amplification refractory mutation
system; BCL, B-lymphoblastoid cell lines; TAP, transporter associated
with antigen processing.
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washed, and aliquots of 5 
 
3
 
 10
 
3
 
/well in 100 
 
m
 
l were used in du-
plicates. Targets were labeled with 
 
51
 
Cr and washed a total of three
times before use in the assay. Effectors were added to each well in
100 
 
m
 
l and incubated with targets for 4–6 h. Percent lysis was cal-
culated from the formula: 100 
 
3
 
 (E 
 
2
 
 M)/(T 
 
2
 
 M), where E
was the chromium release from 20 
 
m
 
l supernatant of wells con-
taining targets and effectors, M the release from wells containing
targets and medium only, and T the release from wells containing
targets and 5% Triton X-100. Where the chromium release from
duplicate wells differed by 
 
.
 
15% from the mean, the data were
discarded. Spontaneous release (M/T) was always 
 
,
 
30%. Percent
of specific lysis was calculated by subtracting percent lysis of tar-
gets pulsed with no peptide or infected with the control flu–vac-
cinia from percent lysis of targets pulsed with peptide or infected
with HIV-1 protein–vaccinia, respectively.
 
Amplification, Cloning and Sequencing of Proviral DNA.
 
Full-length
p17 
 
gag
 
 was amplified from proviral DNA isolated from PHA-acti-
vated PBMC using nested PCR. The primers used were: 5
 
9
 
-GTT-
CTAGGTGATATGG-3
 
9
 
, 5
 
9
 
-ACTAGCGGAGGCTAG-3
 
9
 
 for
the primary reaction; and 5
 
9
 
-AATTCCATGGGTGCGAGA-
GCGT-3
 
9
 
 and 5
 
9
 
-CAGTTCTAGATCTAGTAATTTTGGGCT-
GACC-3
 
9
 
 for the secondary reaction. PCR products were cloned
into the T vector system (Amersham) and epitopes sequenced with
insert-specific primers using the Sequenase Version 2.0 protocol
(USB, Cleveland, OH).
 
Results
 
CTL Responses, CD4 Count, and Virus Load in Two HLA-
identical Siblings Infected at the Same Time.
 
The HLA class I
and class II tissue type of the HLA-identical siblings, donors
003 and 023, was the following: HLA-A
 
*
 
0201, -A
 
*
 
03 -B
 
*
 
07,
-B
 
*
 
51 -Bw
 
*
 
4, -Bw6 -Cw
 
*
 
7, -Cw14 -DR
 
*
 
1, -DR
 
*
 
8 -DQ
 
*
 
4,
-DQ
 
*
 
5. The respective CD4 counts and virus load are
shown in Fig. 1 
 
a.
 
 The CTL response profile was quite dif-
ferent in the two brothers (Fig. 1 
 
b
 
, Table 1). CTL from do-
nor 003 recognized the HLA-A
 
*
 
0201–restricted peptide
SLYNTVATL as the immunodominant response, but two
HLA-A3–restricted epitopes within p17 Gag, one in Nef,
and one in Env were also seen by CTL from this donor.
The dominant responses identified in donor 023 were to
two HLA-B7–restricted epitopes not previously described
(Fig. 1 
 
b
 
), one in p24 Gag, and one in Nef, neither of which
was recognized by CTL from donor 003. A relatively weak
response to the HLA-A
 
*
 
0201 epitope in Pol ILKEPVHGV
was identified in bulk-cultured lymphocytes from donor
023. This peptide was not seen in the bulk response by
003, although it could be seen as a weak response when
PBMC were stimulated directly by the peptide (Fig. 1 
 
c
 
).
Conversely, no responses were observed in donor 023 to
the HLA-A
 
*
 
0201– and HLA-A3–restricted p17 Gag epitopes,
the strongest responses observed in bulk CTL from donor
003 (Fig. 1 
 
b
 
). This pattern of Gag-specific CTL responses ob-
served in donors 003 and 023 has been stable since 1986 (31).
 
timepoint, January, 1996; very similar responses were observed from
timepoint July, 1996. (
 
c
 
) Peptide stimulation of PBMC allows detection
of Pol-specific CTL in donor 003 and Gag-specific CTL in donor 023.
Assay timepoint, June, 1994; very similar responses were observed from
the December, 1994 timepoint.
 
Figure 1.
 
(
 
a
 
) Serial CD4 counts and latest viral loads in donors 003 and
023. (
 
b
 
) Pattern of recognition of CTL epitopes in bulk cultured lympho-
cytes from donors 003 and 023. E/T ratio, 50:1. Only peptides recog-
nized by lymphocytes from 003 or 023 are shown. HLA-A
 
*
 
0201–restricted
epitopes, SLYNTVATL and ILKEPVHGV; HLA-A3–restricted epitopes,
KIRLRPGGK, QVPLRPMTYK, TVYGVPVWK (reference 17), and
RLRPGGKKK; HLA-B7–restricted epitopes, GPGHKARVL and HSQ-
RRQDILDLWIY (Goulder, P.J.R., unpublished data). Lysis of targets
pulsed with no peptide subtracted to calculate percent specific lysis. Assay
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Gag–Vaccinia-infected Targets from Donor 023 Efficiently
Present the SLYNTVATL Gag Epitope to 003 CTL, and Pol–
Vaccinia-infected Targets from Donor 003 Efficiently Present the
ILKEPVHGV Pol Peptide to 023 CTL.
 
One potential ex-
planation for the relative failure of donors to generate a re-
sponse to a particular epitope is that autologous antigen-
presenting cells may fail to process it. The possibility of
processing polymorphism being associated with a particular
response was not the explanation in donors 003 and 023,
who are HLA class I and class II identical. Using Gag–vac-
cinia-infected BCL from 023 and from an HLA-A
 
*
 
0201–
matched donor (5M) as targets, the Gag peptide SLYNT-
VATL was processed and presented as efficiently to 003
bulk CTL as by autologous BCL (Fig. 2 
 
a
 
). Likewise, BCL
from Gag responders were able to process and present the
Figure 2. (a) Bulk cultured CTL from donor 003 recognized Gag–vac-
cinia-infected BCL targets from donor 023 (who made no HLA-A2– or
HLA-A3–restricted Gag response; HLA-identical) and from donor 5M (a
Gag responder; HLA matched through HLA-A*0201 and HLA-B51). E/T
ratio, 18:1 and 76:1 as shown. Recognition of targets pulsed with 10 mm
SLYNTVATL also is shown. Lysis of targets pulsed with no peptide or
infected with control PB2–vaccinia subtracted to calculate percent spe-
cific lysis. In separate assays, BCL from Pol responders 023, 065, and 008
similarly presented the SLYNTVATL epitope to Gag-specific effectors
from donors 102, 077, and 868 (data not shown). (b) HLA-A*0201–
restricted ILKEPVHGV (Pol)-specific line from donor 023 recognized
Pol–vaccinia-infected BCL targets from two Gag responders, 003 (HLA-
identical) and 5M (matched through HLA-A*0201 and HLA-B51). Rec-
ognition of BCL targets pulsed with 10 mm ILKEPVHGV also is shown.
In separate assays, BCL from Gag responders 46M and 868 similarly pre-
sented the ILKEPVHGV epitope to Pol-specific effectors from donors
241, 46M, and 868 (data not shown).
Table 1. HLA-A*0201–positive Donors Tested
Donor
Gag
response
Pol
Response
HLA-A and
HLA-B type
Gag Responders
1 003 40 3 A2/3 B7/51
2 031 28 14 A1/2 B51/57*
3 077 22 10 A2/3 B41/49
4 079 10 3 A2/32 B7/27
5 102 22 4 A2/– B7/57
6 104 28 4 A2/11 B7/62
7 324 12 6 A2/11 B7/60
8 1M 50 2 A1/2 B7/57
9 2M 29 3 A2/6802 B42/51
10 5M 52 2 A2/32 B7/57
11 22M 18 6 A2/6802 B41/72
12 25M 12 5 A2/3 B7/60
13 46M 23 11 A1/2 B8/62
14 48M 34 ND A2/29 B35/44*
15 114 23 12 A2/3 B35/–*
16 868 38 23 A2/24 B27/35
Pol Responders
1 023 3 10 A2/3 B7/51
2 008 2 21 A2/6801 B8/65
3 241 6 30 A2/26 B39/62
4 065 4 38 A1/2 B8/44
5 824 0 11 A1/2 B44/57
Equal Gag and Pol/Nonresponders
1 069 21 21 A2/31 B60/62
2 606 3 1 A2/2 B62/65
3 SC7 2 0 A1/2 B7/44*
HLA class I -A and -B types shown. Gag responders: bulk CTL at E/T
50:1 recognizes the Gag epitope SLYNTVATL, with percent specific
lysis .10% (after subtraction of lysis of targets pulsed with no peptide).
Specific killing of ILKEPVHGV (Pol) pulsed targets (10 mm) is shown.
Pol responders: dominant HLA-A*0201–restricted response is to the
Pol epitope. Equal responders: no preference for Gag or Pol epitope.
The bulk responses of most of the donors was assayed on several (2–6)
occasions; those asterisked were assayed on a single occasion only.
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Pol peptide very efficiently (Fig. 2 b). Gag–vaccinia-infected
BCL from other Gag nonresponders (see below) similarly
were able to present SLYNTVATL efficiently to 003 CTL
(data not shown).
Analysis of p17 Gag Sequences from Proviral DNA in Donors
003 and 023. Provirus DNA from donor 003 does not
differ significantly from the consensus B clade (wild-type)
Gag sequence, and in particular, no deviation from the wild-
type sequence encoding the two immunodominant epitopes
SLYNTVATL (HLA-A*0201) and RLRPGGKKK (HLA-
A3; our unpublished data) was seen in more than 40 clones
(Table 2). In contrast, proviral DNA from donor 023 dif-
fers strikingly from the wild-type sequence. The proviral
sequences from 023 encoding the two epitopes best recog-
nized by CTL from 003 were significantly altered, encod-
ing the peptides SLHNAVAVL and RLRPGGKKC in
Figure 3. (a) Recognition of SLYNTVATL variants by a SLYNTVATL-specific line from donor 868; E/T 3:1. Lysis of targets pulsed with no peptide
subtracted to calculate percent specific lysis. This assay was repeated on three occasions with the same pattern of peptide recognition (data not shown).
Bulk-cultured lymphocytes from donor 003 also showed no recognition of the SLHNAVAVL variant (0% specific lysis) compared with recognition of
SLYNTVATL (45% specific lysis) (data not shown). (b) Recognition of the HLA-A3–restricted peptide epitope RLRPGGKKK by bulk-cultured CTL
from donor 003, and the variant RLRPGGKKC (encoded by proviral DNA within donor 023); E/T ratios as shown. Peptide concentrations, 50 mM.
Peptide titration assays were also performed using a peptide-specific line from donor 003: the variant peptide RLRPGGKKC was not recognized at pep-
tide concentrations of below 50 mM, whereas the index peptide was recognized above peptide concentrations of 5 nM (data not shown). (c) Recognition
of defined HLA-A*0201–, HLA-B8–, and HLA-B62–restricted CTL epitopes (references 17 and 38) by bulk-cultured CTL from donor 46M (HLA class I
-A and -B tissue type: HLA-A1/2 -B8/62) at two timepoints: March, 1995, and December, 1996. Bulk CTL cultured for 15–16 d in each case before as-
say. E/T ratio, 100:1. Peptide concentrations: 10 mM. A2 Gag, SLYNTVATL. A2 Pol, ILKEPVHGV. B8 17.3, GGKKKYKL. B8 17.8, ELRSLYNTV.
B8 24.13, EIYKRWII. B8 24.20, DCKTILKAL. B8 Pol, GPKVKQWPL. B8 Nef 1, WPTVRERM. B8 Nef 8, FLKEKGGL. B62 p24,
GLNKIVRMY. B62 Pol, ILKEPVHGVY. B62 Nef, TQGYFPDWQNY. (d) SLYNTVATL-specific killing is not detectable in peptide-specific lines
stimulated using SLFNTVATL, but is generated using the index peptide to stimulate PBMC from donor 46M. E/T ratios: SLFNTVATL line, 14:1;
SLYNTVATL line, 6:1. Lysis of targets pulsed with no peptide subtracted to calculate percent specific lysis. Assay performed at day 16 of culture; the
same result was observed at day 23 of culture (data not shown).
 o
n
 June 16, 2016
jem.rupress.org
D
ow
nloaded from
 
Published April 21, 1997
1428 Immunodominance in CTL Responses in HLA-identical Siblings with HLA-2
100% of sequences cloned from the most recent timepoint.
No response to these peptides or the wild-type peptides
was seen in bulk CTL from donor 023 (see Fig. 1 b; data
not shown) and no response was made to the variant pep-
tides by bulk CTL from donor 003 (Fig. 3 b; data not
shown). The distinctive epitope changes (His for Tyr at
position 3 in the SLYNTVATL epitope) observed in
proviral DNA from donor 023 have been stably present at
least since the earliest timepoint sequenced, a period of al-
most a decade, and similarly the wild-type sequence has
been stable within donor 003 for this duration (Table 2).
Thus, the two immunodominant responses in 003 may be
absent in 023 because both epitopes have mutated to non-
recognized forms.
SLYNTVATL-specific CTL Dominate the HLA-A*0201–
restricted in 24 HIV-infected Donors. To determine which of
these responses was typical of HIV-positive donors with
HLA-A*0201, we determined the HLA-A*0201–restricted
CTL responses in 22 further donors, using autologous vi-
rus-infected activated T cells to stimulate the responses.
One hemophiliac donor, 008, was infected by the same
batch of contaminated Factor VIII as 003 and 023. One
donor made no detectable CTL response (SC7), and in two
donors there was an equal response to the Gag and Pol
epitopes (069, responses to both peptides; and 606, re-
sponses to neither). The response in donor 48M to the Pol
peptide was not tested. Bulk CTL from 15 of the other 20
donors preferentially responded to the Gag epitope, while
5 (including 023 and 008) preferentially responded to the
Pol epitope.
Provirus Sequences from Gag Nonresponders Encoding the Gag
Epitope Show a Greater Divergence from the Consensus Se-
quence. Analysis of the p17 gag sequences within Gag re-
sponders shows that there is little divergence away from the
wild-type sequence (Table 2). In contrast, there was greater
variation in this region in sequences from Gag nonre-
Table 2. Deduced Amino Acid Sequence around SLYNTVATL Epitope from Proviral DNA Sequence in Responders and Nonresponders
Donor HLA class I A and B type Timepoint Deduced amino acid sequence % Provial DNA clones
SLYNTVATL Responders
003 A2/3 B7/51 07/87 GSEELRSLYNTVATLYCVHQR 100% n 5 8
06/95 GSEELRSLYNTVATLYCVHQR 82% n 5 13
GSEERKSLYNTVATLYCVHQR 6% n 5 1
GSEELRSLLNTVATLYCVHQR 6% n 5 1
GSEELKSLYNTVATLYCVHKR 6% n 5 1
12/95 GSEELRSLYNTVATLYCVHQR 100% n 5 16
06/96 GSEELRSLYNTVATLYCVHQR 100% n 5 5
077 A2/3 B41/49 12/94 GSEELRSLYNTVATLYCVHQR 100% n 5 3
1M A2/1 B7/57 08/96 GSEERKSLYNTVATLYCVHQK 100% n 5 4
5M A2/32 B7/57 10/93 GSEELRSLYNTIAVLYCVHQR 90% n 5 28
GSEELRSLYNTVAVLYCVHQR 10% n 5 3
11/95 GSEEVRSLYNTVATLYCVHQR 100% n 5 4
868 A2/24 B27/35 10/95 GSEELRSLYNTVATLYCVHQR 73% n 5 8
GSEELRSLYNTIATLYCVHQR 9% n 5 1
GSEELKSLYNTIATLYCVHQR 9% n 5 1
GSEERKSLYNTVATLYCVHQR 9% n 5 1
04/96 GSEELRSLYNTIAVLYCVHQR 92% n 5 11
GSEELKSLYNTIATLYCVHQR 8% n 5 1
08/96 GSEELKSLYNTVATLYCVHQR 100% n 5 5
SLYNTVATL Nonresponders
023 A2/3 B7/51 07/87 GSEKLKSLHNTVATLYCVHQR 100% n 5 3
06/95 GSEELQSLHNAVAVLYCVHQR 70% n 5 7
GSEELESLYNTVATLYCVHQR 10% n 5 1
GSEELKSLYNTVATLYCVHQR 10% n 5 1
GSEELKSLSNTIATLYCVHQR 10% n 5 1
12/95 GSEELQSLHNAVAVLYCVHQR 100% n 5 10
07/96 GSEELQSLHNAVAVLYCVHQR 100% n 5 16
008 A2/68 B8/65 04/91 GSEEFRSLFNTVATLYCVHQR 50% n 5 3
Continued
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sponders. In donors 008 and 606 (Gag nonresponders), the
encoded Gag peptides were not well recognized by pep-
tide-specific CTL, whereas variation transiently observed in
the Gag responder 868 did not affect CTL recognition (Fig.
3 a). Although mutations within the epitope and within
amino acids flanking the epitope were observed more fre-
quently in Gag nonresponders, some nonresponders (065 and
241) carried proviral sequences encoding changes within
the epitope that did not alter CTL recognition, and some
Gag responders carry sequences encoding changes flanking
the epitope (1M, 868).
Switch from Gag Responder to Nonresponder in Donor 46M
Coincided with Fixation of a Sequence Change Resulting in Fail-
ure to Recognize the Epitope. When bulk cultured CTL from
donor 46M were first assayed in 1994, a clear response to
the SLYNTVATL Gag epitope was observed. Subse-
quently, this response has disappeared (Fig. 3 c), while other
responses remain readily detectable. In 1994, 50% of autolo-
gous provirus sequences encoded the index peptide; 2 yr
later, 100% of sequences encode the variant SLFNTVATL
(Table 2). This Tyrfi Phe change at position 3 in the epitope
results in poor CTL recognition (Fig. 3 a). In all Gag non-
responders tested so far (023, 241, 065, 606, and 46M;
timepoint 12/96) stimulation of PBMC with the SLYNT-
VATL peptide allowed detection of SLYNTVATL-specific
CTL (specific lysis at E/T ratio of 5:1 ranging from 9 to
40%; Fig. 3 c; data not shown), but stimulation of 46M
PBMC with the SLFNTVATL variant did not result in the
generation of any peptide-specific CTL (Fig. 3 d).
Discussion
CTLs play a central role in the immune response to virus
infections, as well as to other intracellular pathogens and to
tumor cells. The importance of CTL at all stages of HIV
infection is increasingly apparent. There is also growing ev-
idence that there are qualitative differences in the responses
generated by infected individuals, and that these may influ-
ence the long-term control of the infection and, ultimately,
the prognosis. The determinants of immunodominance of
MHC class I–restricted CTL responses are of considerable
relevance to disease progression.
Table 2. Continued
Donor HLA class I A and B type Timepoint Deduced amino acid sequence % Proviral DNA clones
GSEEFRSLFNTVATLYCVHQK 17% n 5 1
GSEEFRSLLNTVATLYCVHQR 17% n 5 1
GSEEFRSLSNTVATLYCVHQR 17% n 5 1
04/92 GSEELKSLFNTVAVLYCVHQR 38% n 5 8
GSEELRSLFNTVAVLYCVHQR 19% n 5 4
GSEELKSLFNTIAVLYCVHQR 10% n 5 2
GSEEFRSLFNTVATLYCVHQR 5% n 5 1
GSEELKSLFNTVATLYCVHQR 14% n 5 3
GSEELRSLYNTIAVLYCVHQR 14% n 5 3
065 A2/1 B8/44 02/93 GSEELKSLYNTVATLYCVHQR 100% n 5 28
08/94 GSEELKSLYNTVATLYCVHQR 100% n 5 1
05/96 GSEELKSLYNTVATLYCVHQR 100% n 5 2
GSEELRSLYNTVATLYCVHQR 100% n 5 1
241 A2/26 B39/62 02/93 GSEELKSLYNTIATLYCVHQQ 100% n 5 6
606 A2/- B62/65 10/94 GSEELKSLFNTVATLYCVHKR 75% n 5 3
GSEELKSLFNTVAVLYCVHKR 25% n 5 1
SLYNTVATL Responder Switched to Nonresponder
46M A2/1 B8/62 09/94 GSEELRSLYNTVATLYCVHQR 33% n 5 6
GSEELKSLYNTVATLYCVHQR 17% n 5 3
GSEELRSLFNTVATLYCVHQR 11% n 5 2
GSEELKSLFNTVATLYCVHQR 39% n 5 7
06/95 GSEELKSLFNTVATLYCVHQR 100% n 5 2
04/96 GTEELRSLFNTVATLYCVHQR 100% n 5 3
Proviral DNA sequences and the encoded amino acid sequences at the region of the Gag epitope for five Gag responders, five nonresponders, and
one donor whose Gag response disappeared between the first timepoint and the last; showing the timepoint (mo/yr), amino acid sequence (SLYN-
TVATL epitope underlined, with six amino acids either side of the epitope shown; differences from HIVLAI sequence shown in bold); number of
clones sequenced, and proportion encoding a particular amino acid sequence.
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We have studied the HIV-specific CTL responses di-
rected through the commonest HLA class I molecule found
in caucasoid and many other populations, HLA-A*0201 (32).
The majority of donors recognise the Gag epitope SLYN-
TVATL predominantly, and a minority, the Pol epitope,
ILKEPVHGV. Because the response is not universally di-
rected towards one epitope rather than the other, the ex-
planation cannot lie solely in differences of affinity of the
peptides to HLA-A*0201. In fact, our binding studies show
that the Pol peptide binds significantly better than the Gag
peptide (data not shown), and other studies have similarly
shown very strong binding of the Pol peptide to HLA-A2
(33). This is consistent with what is known of the peptide-
binding motif for HLA-A*0201, where the preferred an-
chor residues are leucine at position 2 and valine at position
9 (COOH-terminal anchor, PC). Of 16 HLA-A*0201–
restricted CTL epitopes listed (34), 12 had valine at PC, 2
had leucine. A previous study comparing the relative binding
affinities of polyalanine substituted amino acids to HLA-
A*0201 showed that the substitution of valine for leucine at
PC resulted in a 10-fold increase in relative binding (35).
The predominance of CTL responses to the Gag epitope
is in better agreement with data estimating the abundance
of each peptide on the cell surface, where .30 times as
many SLYNTVATL molecules were present on the surface
of stably infected Jurkat-A2 cells as ILKEPVHGV mole-
cules (27). We investigated the possibility that HIV-infected
cells from Gag responders might be presenting the SLYN-
TVATL peptide more efficiently than the Pol peptide, but
experiments using Gag–vaccinia-infected BCL did not sup-
port this (Fig. 2 a; data not shown). Similarly, BCL from Gag
responders, when infected with Pol–vaccinia, presented the
Pol peptide at least as well as Pol–vaccinia-infected BCL
from a Pol responder (Fig. 2 b).
The observation has often been made that HIV-specific
CTL epitopes tend to cluster in immunodominant regions
of proteins (17). Because of the report of HLA-B8 and
HLA-B*2702 MHC class I molecules competing for the pre-
sentation of the overlapping influenza-specific epitopes EL-
RSRYWAI and LRSRYWAI (36), the possibility was raised
that this phenomenon might influence immunodominance
of HIV-specific CTL responses similarly. Whereas donor 065
generated no response to the Gag epitope SLYNTVATL, a
strong response was made to the HLA-B8–restricted over-
lapping epitope ELRSLYNTV (Goulder, P.J.R., S.W. Reid,
D.A. Price, A.J. McMichael, R.E. Phillips, and E.Y. Jones,
manuscript submitted for publication), and a weaker re-
sponse to the HLA-A1–restricted epitope, GSEELRSLY
(our unpublished data). Although Gag–vaccinia-infected
HLA-A*0201/B8 targets appeared to express the SLYNT-
VATL epitope adequately (data not shown), we cannot ex-
clude that competition between MHC molecules for over-
lapping epitope peptides could influence the development
of immunodominance of the response, favoring a predomi-
nant response to the Pol epitope in this donor.
Donors 003 and 023 are two HLA-identical brothers
who were infected by a virus at the same time, probably
the same quasispecies of virus, at a very similar dose. Nei-
ther donor has progressed to disease over 12 yr of infection.
Donor 003 has a virus load below the level of detection
(,500 RNA copies/ml), and that of donor 023 is low
(8,500 RNA copies/ml plasma); neither has received anti-
retroviral therapy. The CTL responses are quite different,
which demonstrates that, in this instance, the pattern of re-
sponse is not determined solely by the HLA genotype, or
by TAP polymorphism or by proteasome-related process-
ing effects.
It is difficult to demonstrate unequivocally that viral iso-
lates from the two individuals have derived from a single
original virus, because selection acting early on in the course
of infection may have resulted in dramatically divergent se-
quences. Unfortunately, we do not have access to the con-
taminated batch of Factor VIII believed to have infected
these two brothers, and the earliest sequence available for
analysis is 3 yr after infection. Comparison of p17 gag se-
quences would show major dissimilarities between 003 and
023 sequences, because (as argued below) selection pressure
exerted by CTL early on in infection has resulted in epi-
tope variation and switching of immunodominant responses
to different epitopes in donor 023. Neighboring sequences
outside epitopes might be expected to show compensatory
changes, increasing the interindividual sequence divergence
further. Comparison of other regions (such as env) of the
genome might be equally misleading because of different
selective pressures acting on the viruses in the two brothers.
The clear epidemiological evidence that these brothers
were infected with the same original virus is the detailed
documentation that throughout life they have shared iden-
tical supplies of Factor VIII, they were exposed at the same
time exclusively to one particular batch of Factor VIII, and
shortly afterwards both brothers seronconverted. Donors
003 and 023 are now 27 and 25 yr of age, respectively, and
first became seropositive within 10 wk of one another (De-
cember, 1983 and February, 1984) when aged 12 and 10 yr,
having been exposed by home-administered treatment ex-
clusively to the same batch of non–heat-treated Factor VIII
between August and December, 1983.
The study by Tsomides et al. (27) implies that an excess
of the Gag SLYNTVATL epitope compared with the Pol
ILKEPVHGV epitope is presented by infected CD41 cells
in both donor 003 and donor 023 (27). The remarkable differ-
ence between these two donors is in the provirus sequence
encoding the Gag epitope. The peptide encoded by 100%
of provirus from donor 023, SLHNAVAVL, is not recog-
nized by autologous bulk CTL or Gag-specific CTL lines
(Fig. 3 a). Equally striking is the sequence change observed
in provirus from donor 023 encoding the HLA-A3–restricted
epitope, RLRPGGKKK, the second of two dominant re-
sponses in donor 003 (Fig. 1 b). In this case, the PC anchor
lysine residue is switched to a cysteine, a change resulting in
abrogation of recognition by CTL from donor 003 (Fig. 3
b). (No epitope peptide has been described with a cysteine
at the COOH terminus [34], so this peptide may not even
be processed or transported.) This combination of muta-
tions is unique for each epitope, when compared with 32 B
clade Gag amino acid sequences in the database (38). It is
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also noteworthy that the unusual Tyrfi His sequence change
has been stable for at least 9 yr.
Are the unique sequence changes observed in the provi-
rus of donor 023 and the unusual preference in the CTL
response of this donor for the Pol epitope causally con-
nected? In another hemophiliac donor, 008, also probably
infected by the same viral quasispecies as donors 003 and
023, provirus also encodes an epitope that is not recognized
by Gag-specific CTL, and this donor, too, is unusual in
being a Pol responder. Together with the PC anchor se-
quence change observed within the HLA-A3–restricted epi-
tope RLRPGGKKK in donor 023 provirus, these data are
suggestive of CTL escape occurring early on in infection and
strongly influencing the subsequent stable pattern of CTL
response observed. In donor 023, two mutations together
might permit escape from both CTL epitopes, whereas in
003 this does not occur, perhaps because of the presence of
other CTL responses.
The disappearance of a bulk response to SLYNTVATL
in donor 46M in association with the increased frequency
to fixation of the F3 variant is suggestive that this pattern of
events may have occurred in other Gag nonresponders. In
support of this is the finding that SLYNTVATL-specific
CTL could be detected using the sensitive method of pep-
tide stimulation of PBMC in all Gag nonresponders tested,
implying the presence of memory CTL. Use of SLYNT-
VATL–HLA-A*0201 complexes (39) has shown that some
Gag nonresponders nonetheless have a relatively high fre-
quency of SLYNTVATL-specific effectors within PBMC,
which implies that these Gag nonresponders have previ-
ously generated SLYNTVATL-specific responses that are no
longer active.
A previous study described two donors with HLA-A11
and three other donors with HLA-B18, who made CTL
responses to Nef-specific epitopes, provided that autologous
virus sequences did not show mutations that abrogated CTL
recognition (40). The data we describe show that such
epitope variation is not necessary for a failure of a response
towards the epitope to be observed; but often this is the
case, and may be the result of multiple early escape muta-
tions, occurring within 3 yr of seroconversion. Studies of
CD81 TCR Vb usage after seroconversion have illustrated
the spectacular Vb-specific expansions and deletions that
occur rapidly at this time (41). The swift emergence of CTL
escape mutations at seroconversion has also been well de-
scribed (42–43). The precise relationship of these dramatic
fluctuations to escape variation within the cognate epitope
has not been determined.
It is clear from these data that early escape mutation
within the normally immunodominant epitope SLYNT-
VATL is not the only factor determining the pattern of an
individual CTL response. It is possible, as in the Pol re-
sponder 065 (whose sequence carries no mutations within
the epitope), that competition between class I molecules
for overlapping epitopes may have an influence. In this study,
we have not investigated the role of flanking mutations,
which occurred universally in the Gag nonresponder group
(including 065) and relatively infrequently in the Gag re-
sponder group (Table 2). The clustering of nonsynonymous
mutations at sites flanking HIV-specific CTL epitopes has
been noted previously (40, 44), and flanking changes have
been demonstrated to affect presentation in some systems
(19, 45).
In summary, the immunodominance of CTL responses in
two HLA-identical siblings, probably infected by the same
quasispecies of virus and at the same time, is not determined
by HLA genotype or processing differences alone. The CTL
responses in HLA-A*0201 seropositive donors to two well-
defined HLA-A*0201–restricted epitopes is likely to be de-
termined primarily by the high abundance on the cell sur-
face of the Gag epitope relative to the Pol epitope. In the
minority of individuals who fail to respond to the Gag
epitope, mutation within the Gag epitope occurring early
in infection that abrogates CTL recognition may influence
the pattern of the CTL response away from the Gag epi-
tope. In addition, variation within flanking regions, reduc-
ing the presentation of the Gag epitope, or competition by
other HLA class I molecules for epitopes overlapping with
the Gag epitope, may also determine the pattern of the
CTL response.
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